Skip to main content
# Table 1
**Input parameters used in economic model**

Parameter | Distribution | Mean | SE | Reference |
---|---|---|---|---|

Yearly discount rate (%)
| ||||

Costs and outcomes (range) | 3 (0-6) | [51] | ||

Transitional probability baseline parameters
| ||||

Probability of stable to CHB state | Beta | 0.143 | 0.0650 | [31] |

Probability of CHB to stable state | Beta | 0.056 | 0.0180 | [32] |

Probability of CHB to compensated in 1^{st}-10^{th} year
| Beta | 0.054 | 0.0543 | [33] |

Probability of CHB to compensated in 11^{th}-20^{th} year
| Beta | 0.134 | 0.1338 | [33] |

Probability of CHB to compensated in >20^{th} year
| Beta | 0.329 | 0.3292 | [33] |

Probability of CHB to HCC in 1^{st}-5^{th} year
| Beta | 0.000 | 0.0000 | [34] |

Probability of CHB to HCC in 6t^{h}-10^{th} year
| Beta | 0.006 | 0.0061 | [34] |

Probability of CHB to HCC in >10^{th} year
| Beta | 0.008 | 0.0081 | [34] |

Probability of CHB to death in 1^{st}-5^{th} year
| Beta | 0.010 | 0.0102 | [34] |

Probability of CHB to death in 6^{th}-10^{th} year
| Beta | 0.014 | 0.0144 | [34] |

Probability of CHB to death in >10^{th} year
| Beta | 0.025 | 0.0252 | [34] |

Probability of compensated to decompensated in 1^{st}-3^{rd} year
| Normal | 0.042 | 0.0003 | [35] |

Probability of compensated to decompensated in 4^{th}-5^{th} year
| Normal | 0.094 | 0.0005 | [35] |

Probability of compensated to decompensated in >5^{th} year
| Normal | 0.066 | 0.0003 | [35] |

Probability of compensated to HCC in 1^{st}-3^{rd} year
| Normal | 0.014 | 0.0002 | [35] |

Probability of compensated to in HCC 4^{th}-5^{th} year
| Normal | 0.036 | 0.0003 | [35] |

Probability of compensated to HCC in >5^{th} year
| Normal | 0.030 | 0.0002 | [35] |

Probability of compensated to death in 1^{st}-3^{rd} year
| Beta | 0.014 | 0.0135 | [35] |

Probability of compensated to death in >3^{rd} year
| Beta | 0.046 | 0.0461 | [35] |

Probability of decompensated to HCC | Beta | 0.035 | 0.0354 | [36] |

Probability of decompensated to death in 1^{st} year
| Normal | 0.260 | 0.0004 | [37] |

Probability of decompensated to death in 2^{nd} year
| Normal | 0.390 | 0.0005 | [37] |

Probability of decompensated to death in >2^{nd} year
| Normal | 0.240 | 0.0003 | [37] |

Probability of HCC to death in 1^{st} year
| Beta | 0.848 | 0.0011 | [37] |

Probability of HCC to death in >1^{st} year
| Beta | 0.920 | 0.0009 | [37] |

Transitional probability of treatment parameters
| ||||

Probability of CHB to compensated | Beta | 0.006 | 0.0023 | [38] |

Probability of CHB to HCC | Beta | 0.009 | 0.0045 | [39] |

Probability of CHB to death | Beta | 0.002 | 0.0023 | [39] |

Probability of compensated to HCC | Beta | 0.015 | 0.0034 | [40] |

Probability of compensated to death | Beta | 0.007 | 0.0070 | [39] |

Probability of decompensated to HCC | Beta | 0.035 | 0.0127 | [41] |

Probability of decompensated to death | Beta | 0.126 | 0.0291 | [42] |

Probability of compensated to CHB | Beta | 0.478 | 0.0665 | [43] |

Probability of HCC to death | Beta | 0.034 | 0.0227 | [44] |

Relative risk of seroconversion of lamivudine | Normal | 3.519 | 1.3707 | [30] |

Relative risk of seroconversion of adefovir | Normal | 3.028 | 1.3833 | [30] |

Relative risk of seroconversion of telbivudine | Normal | 4.286 | 1.4054 | [30] |

Relative risk of seroconversion of entecavir | Normal | 3.846 | 1.3833 | [30] |

Relative risk of seroconversion of pegylated interferon | Normal | 5.356 | 1.4987 | [30] |

Relative risk of seroconversion of tenofovir | Normal | 4.167 | 1.6403 | [30] |

Probability of delay seroconversion of pegylated interferon | Normal | 0.410 | 0.0489 | [27] |

Probability of lamivudine resistance | Beta | 0.214 | 0.0214 | [28] |

Probability of adefovir resistance | Beta | 0.066 | 0.0066 | [28] |

Probability of telbivudine resistance | Beta | 0.089 | 0.0089 | [28] |

Probability of entecavir resistance | Beta | 0.002 | 0.0002 | [28] |

Probability of tenofovir resistance | Beta | 0.000 | 0.0000 | [28] |

Annual direct medical cost
| ||||

Cost of generic lamivudine | Gamma | 1,797 | 180 | [46] |

Cost of original lamivudine | Gamma | 34,871 | 3,487 | [46] |

Cost of adefovir | Gamma | 70,298 | 7,030 | [46] |

Cost of telbivudine | Gamma | 51,504 | 5,150 | [46] |

Cost of entecavir | Gamma | 85,745 | 8,575 | [46] |

Cost of tenofovir | Gamma | 15,559 | 1,556 | [46] |

Cost of pegylated interferon | Gamma | 527,379 | 52,738 | [46] |

Cost of treatment of compensated cirrhosis | Gamma | 81,264 | 81,264 | [48] |

Cost of treatment of decompensated cirrhosis | Gamma | 125,127 | 125,127 | [48] |

Cost of treatment of HCC | Gamma | 153,021 | 153,021 | [48] |

Cost of laboratory for screening (i.e., HBeAg, HBeAb) | Gamma | 650 | 650 | [47] |

Cost of laboratory for pre-treatment | Gamma | 3,350 | 3,350 | [47] |

Cost of laboratory for monitoring | Gamma | 4,200 | 4,200 | [47] |

Cost of laboratory monitoring for pegylated interferon | Gamma | 10,620 | 10,620 | [47] |

Cost of laboratory monitor for adefovir | Gamma | 4,560 | 4,560 | [47] |

Cost of laboratory for post-treatment | Gamma | 4,900 | 4,900 | [47] |

Annual direct non-medical cost
| ||||

Cost of transportation | Gamma | 571 | 571 | [54] |

Cost of food | Gamma | 210 | 210 | [54] |

Annual indirect cost
| ||||

Cost of time loss due to receiving treatment | Gamma | 824 | 824 | [49] |

Cost of productivity loss of compensated cirrhosis | Gamma | 48 | 48 | [48, 49] |

Cost of productivity loss of decompensated cirrhosis | Gamma | 627 | 627 | [48, 49] |

Cost of productivity loss of HCC | Gamma | 1,701 | 1,701 | [48, 49] |

Utility
| ||||

Utility weight for CHB | Normal | 0.68 | 0.00005 | [53] |

Utility weight for compensated cirrhosis | Normal | 0.69 | 0.00016 | [53] |

Utility weight for decompensated cirrhosis | Normal | 0.35 | 0.00031 | [53] |

Utility weight for HCC | Normal | 0.38 | 0.00026 | [53] |